Community Healthcare Trust officer awarded 17,529 restricted shares; holdings rise to 445,728
Rhea-AI Filing Summary
Leigh Ann Stach, Executive Vice President & CAO of Community Healthcare Trust Inc. (CHCT), acquired 17,529 shares of common stock as restricted stock tied to her 2025 bonus. She elected to take 50% of her cash bonus in restricted shares and the Company awarded additional restricted stock equal to 15% of her cash bonus. The award used an average price of $15.85 based on the 10 trading days before 08/07/2025. The restricted shares carry a three-year restriction period. Following the reported transaction, Ms. Stach beneficially owned 445,728 shares.
This Form 4 reports a compensation-related issuance of restricted stock to an officer, showing the mechanics of the award and the resulting beneficial ownership position.
Positive
- Officer elected to receive 50% of 2025 cash bonus in restricted stock
- Company awarded additional restricted stock equal to 15% of her cash bonus
- Restricted shares carry a three-year restriction period
- Beneficial ownership increased to 445,728 shares
- Price basis for award clearly disclosed as $15.85 (10-day average)
Negative
- None.
Insights
TL;DR: Routine compensation award increases officer ownership to 445,728 shares; transaction size and restrictions are explicitly disclosed.
The filing documents a compensation-driven acquisition of 17,529 restricted shares at an average price of $15.85, reflecting an election to receive half of the 2025 cash bonus in stock plus an additional 15% award of the cash bonus in restricted shares. The three-year restriction period and the resulting beneficial ownership of 445,728 shares are material for understanding the officer's stake and vesting timeline. This is a standard incentive/retention disclosure rather than a market-moving corporate action.
TL;DR: Officer compensation structured with time-based restricted stock; disclosure clarifies award calculation and post-award ownership.
The report clearly states the mechanics: a 50% election of the 2025 cash bonus into restricted stock and an additional award equal to 15% of the cash bonus, priced at the 10-day average of $15.85. The three-year restriction period is explicitly noted, indicating time-based vesting terms. The filing provides transparent reporting of the grant and the change in beneficial ownership, which is relevant for governance oversight and executive compensation records.